CoChat
Sign Up
Cited by 257

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Hypertrophic obstructive cardiomyopathy

Veselka, Josef, Anavekar, Nandan S, Charron, Philippe·2017·The Lancet
DOI 10.1016/s0140-6736(16)31321-6
Open this paper in CoChat — free account

Abstract

Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness ≥15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. Typical symptoms include dyspnoea, chest pain, palpitations, and syncope. The diagnosis is usually suspected on clinical examination and confirmed by imaging. Some patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrillation. Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients with severe symptoms related to ventricular obstruction, septal reduction therapy (myectomy or alcohol septal ablation) is recommended. Life-long anticoagulation is indicated after the first episode of atrial fibrillation.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)31321-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 156

  1. Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  2. Gersh, 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, Circulation, 124, e783
  3. Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases, Eur Heart J, 29, 270, 10.1093/eurheartj/ehm342 · DOI
  4. Vulpian, 1868, Contribution à l'étude des rétrécissements de l'orifice ventriculo-aortique, Arch Physiol, 3, 456
  5. Brock, 1957, Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis, Guys Hosp Rep, 106, 221
  6. Teare, 1958, Asymmetrical hypertrophy of the heart in young adults, Br Heart J, 20, 1, 10.1136/hrt.20.1.1 · DOI
  7. Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 · DOI
  8. Lipshultz, 2003, The incidence of pediatric cardiomyopathy in two regions of the United States, New Engl J Med, 348, 1647, 10.1056/NEJMoa021715 · DOI
  9. Nugent, 2005, Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study, Circulation, 112, 1332, 10.1161/CIRCULATIONAHA.104.530303 · DOI
  10. Charron, 1997, Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population, Circulation, 96, 214, 10.1161/01.CIR.96.1.214 · DOI
  11. Bick Alexander, 2012, Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts, Am J Hum Genet, 91, 513, 10.1016/j.ajhg.2012.07.017 · DOI
  12. Ho, 2015, Genetic advances in sarcomeric cardiomyopathies: state of the art, Cardiovasc Res, 105, 397, 10.1093/cvr/cvv025 · DOI
  13. Kimura, 2016, Molecular genetics and pathogenesis of cardiomyopathy, J Hum Genet, 61, 41, 10.1038/jhg.2015.83 · DOI
  14. Richard, 2003, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 · DOI
  15. Bos, 2014, Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 89, 727, 10.1016/j.mayocp.2014.01.025 · DOI
  16. Gruner, 2013, Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 6, 19, 10.1161/CIRCGENETICS.112.963363 · DOI
  17. Watkins, 1995, Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy, New Engl J Med, 332, 1058, 10.1056/NEJM199504203321603 · DOI
  18. Watkins, 1992, Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy, New Engl J Med, 326, 1108, 10.1056/NEJM199204233261703 · DOI
  19. Charron, 1998, Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene, Circulation, 97, 2230, 10.1161/01.CIR.97.22.2230 · DOI
  20. Niimura, 1998, Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy, New Engl J Med, 338, 1248, 10.1056/NEJM199804303381802 · DOI
  21. Maron, 2001, Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations, J Am Coll Cardiol, 38, 315, 10.1016/S0735-1097(01)01386-9 · DOI
  22. Christiaans, 2011, Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy, Eur Heart J, 32, 1161, 10.1093/eurheartj/ehr092 · DOI · Paper page
  23. Alpert, 2005, Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations, Am J Physiol Heart Circ Physiol, 288, H1097, 10.1152/ajpheart.00650.2004 · DOI
  24. Girolami, 2010, Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations, J Am Coll Cardiol, 55, 1444, 10.1016/j.jacc.2009.11.062 · DOI
  25. Ingles, 2005, Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling, J Med Genet, 42, e59, 10.1136/jmg.2005.033886 · DOI
  26. Marziliano, 2012, A case of compound mutations in the MYBPC3 gene associated with biventricular hypertrophy and neonatal death, Neonatology, 102, 254, 10.1159/000339847 · DOI
  27. Biagini, 2014, Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy, Am J Cardiol, 114, 769, 10.1016/j.amjcard.2014.05.065 · DOI
  28. Fujita, 2013, Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: results from multicenter registration in Japan, JACC Heart Fail, 1, 459, 10.1016/j.jchf.2013.08.007 · DOI
  29. Li, 2014, Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events, Circ Cardiovasc Genet, 7, 416, 10.1161/CIRCGENETICS.113.000331 · DOI
  30. Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.1016/S0025-6196(11)60890-2 · DOI
  31. Colan, 2007, Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry, Circulation, 115, 773, 10.1161/CIRCULATIONAHA.106.621185 · DOI
  32. Rapezzi, 2013, Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on myocardial and pericardial diseases, Eur Heart J, 34, 1448, 10.1093/eurheartj/ehs397 · DOI
  33. Davies, 1995, Hypertrophic cardiomyopathy—pathology and pathogenesis, Histopathology, 26, 493, 10.1111/j.1365-2559.1995.tb00267.x · DOI
  34. Shapiro, 1983, Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study, J Am Coll Cardiol, 2, 437, 10.1016/S0735-1097(83)80269-1 · DOI
  35. Maron, 1979, Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum. Comparison of fetuses and infants with and without congenital heart disease and patients with hypertrophic cardiomyopathy, Circulation, 60, 685, 10.1161/01.CIR.60.3.685 · DOI
  36. Factor, 1991, Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 17, 1343, 10.1016/S0735-1097(10)80145-7 · DOI
  37. Tanaka, 1987, Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy, Circulation, 75, 1130, 10.1161/01.CIR.75.6.1130 · DOI
  38. Cardim, 2015, Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging endorsed by the Saudi Heart Association, Eur Heart J Cardiovasc Imaging, 16, 280, 10.1093/ehjci/jeu291 · DOI
  39. Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 · DOI
  40. Tyska, 2000, Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy, Circ Res, 86, 737, 10.1161/01.RES.86.7.737 · DOI
  41. Teekakirikul, 2012, Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics, J Cell Biol, 199, 417, 10.1083/jcb.201207033 · DOI
  42. Green, 2016, A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice, Science, 351, 617, 10.1126/science.aad3456 · DOI
  43. Cuda, 1993, Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy, J Clin Invest, 91, 2861, 10.1172/JCI116530 · DOI
  44. Witjas-Paalberends, 2013, Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy, Cardiovasc Res, 99, 432, 10.1093/cvr/cvt119 · DOI
  45. Georgakopoulos, 1999, The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an α-cardiac myosin heavy chain missense mutation, Nat Med, 5, 327, 10.1038/6549 · DOI
  46. Knollmann, 2003, Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling, Circ Res, 92, 428, 10.1161/01.RES.0000059562.91384.1A · DOI
  47. Spindler, 1998, Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy, J Clin Invest, 101, 1775, 10.1172/JCI1940 · DOI · Paper page
  48. Schlossarek, 2014, Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy, Front Physiol, 5, 484, 10.3389/fphys.2014.00484 · DOI
  49. McLeod, 2009, Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram, J Am Coll Cardiol, 54, 229, 10.1016/j.jacc.2009.02.071 · DOI
  50. Moon, 2004, Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography, Heart, 90, 645, 10.1136/hrt.2003.014969 · DOI
  51. Rickers, 2005, Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, 112, 855, 10.1161/CIRCULATIONAHA.104.507723 · DOI
  52. Kebed, 2014, Evaluation of apical subtype of hypertrophic cardiomyopathy using cardiac magnetic resonance imaging with gadolinium enhancement, Am J Cardiol, 114, 777, 10.1016/j.amjcard.2014.05.067 · DOI
  53. Kebed, 2014, Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI, Int J Cardiovasc Imaging, 30, 591, 10.1007/s10554-013-0355-y · DOI
  54. Noureldin, 2012, The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 14, 17, 10.1186/1532-429X-14-17 · DOI
  55. Bruder, 2010, Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 875, 10.1016/j.jacc.2010.05.007 · DOI
  56. O'Hanlon, 2010, Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 867, 10.1016/j.jacc.2010.05.010 · DOI
  57. Moon, 2004, The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 43, 2260, 10.1016/j.jacc.2004.03.035 · DOI
  58. Papavassiliu, 2005, CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis, Eur Heart J, 26, 2395, 10.1093/eurheartj/ehi518 · DOI
  59. Moravsky, 2013, Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR, JACC Cardiovasc Imaging, 6, 587, 10.1016/j.jcmg.2012.09.018 · DOI
  60. Kwon, 2009, Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia, J Am Coll Cardiol, 54, 242, 10.1016/j.jacc.2009.04.026 · DOI
  61. Suk, 2008, Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients, Heart Lung Circ, 17, 370, 10.1016/j.hlc.2008.03.080 · DOI
  62. Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 370, 10.1016/j.jcmg.2011.11.021 · DOI
  63. Briasoulis, 2015, Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis, Heart, 101, 1406, 10.1136/heartjnl-2015-307682 · DOI
  64. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  65. Ennis, 2003, Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging, Magn Reson Med, 50, 638, 10.1002/mrm.10543 · DOI
  66. Kim, 2008, Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI, J Magn Reson Imaging, 27, 1054, 10.1002/jmri.21366 · DOI
  67. Cannon, 1985, Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures, Circulation, 71, 234, 10.1161/01.CIR.71.2.234 · DOI
  68. O'Gara, 1987, Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography, Circulation, 76, 1214, 10.1161/01.CIR.76.6.1214 · DOI
  69. Dilsizian, 1993, Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 22, 796, 10.1016/0735-1097(93)90193-5 · DOI
  70. Cannon, 1992, Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy, Circulation, 85, 1039, 10.1161/01.CIR.85.3.1039 · DOI
  71. Maron, 2009, The case for Myocardial Ischemia in Hypertrophic Cardiomyopathy, J Am Coll Cardiol, 54, 866, 10.1016/j.jacc.2009.04.072 · DOI
  72. Olivotto, 2004, Coronary microvascular dysfunctoin and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences, Ital Heart J, 5, 572
  73. Choudhury, 1996, Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy, Eur Heart J, 17, 1703, 10.1093/oxfordjournals.eurheartj.a014754 · DOI
  74. Leschka, 2008, Myocardial bridging: depiction rate and morphology at CT coronary angiography—comparison with conventional coronary angiography, Radiology, 246, 754, 10.1148/radiol.2463062071 · DOI
  75. Morise, 2011, Exercise testing in nonatherosclerotic heart disease: hypertrophic cardiomyopathy, valvular heart disease, and arrhythmias, Circulation, 123, 216, 10.1161/CIRCULATIONAHA.109.914762 · DOI
  76. Gimeno, 2009, Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy, Eur Heart J, 30, 2599, 10.1093/eurheartj/ehp327 · DOI
  77. Desai, 2014, Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes, JACC Cardiovasc Imaging, 7, 26, 10.1016/j.jcmg.2013.08.010 · DOI
  78. Charron, 2010, Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases, Eur Heart J, 31, 2715, 10.1093/eurheartj/ehq271 · DOI
  79. Ingles, 2015, Application of genetic testing in hypertrophic cardiomyopathy for preclinical disease detection, Circ Cardiovasc Genet, 8, 852, 10.1161/CIRCGENETICS.115.001093 · DOI
  80. Jensen, 2015, Echocardiographic evaluation of pre-diagnostic development in young relatives genetically predisposed to hypertrophic cardiomyopathy, Int J Cardiovasc Imaging, 31, 1511, 10.1007/s10554-015-0723-x · DOI
  81. Gandjbakhch, 2010, Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging, Eur Heart J, 31, 1599, 10.1093/eurheartj/ehq101 · DOI
  82. Ho, 2010, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, New Engl J Med, 363, 552, 10.1056/NEJMoa1002659 · DOI
  83. Ho, 2002, Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy, Circulation, 105, 2992, 10.1161/01.CIR.0000019070.70491.6D · DOI
  84. Rowin, 2012, CMR with late gadolinium enhancement in genotype positive–phenotype negative hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 119, 10.1016/j.jcmg.2011.08.020 · DOI
  85. Maron, 2012, Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 5, 441, 10.1161/CIRCIMAGING.112.972760 · DOI
  86. Charron, 1998, Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children, Eur Heart J, 19, 1377, 10.1053/euhj.1998.1049 · DOI
  87. Varnava, 1999, A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy, Heart, 82, 621, 10.1136/hrt.82.5.621 · DOI
  88. Christiaans, 2009, Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy, Heart Rhythm, 6, 1366, 10.1016/j.hrthm.2009.04.029 · DOI
  89. McKenna, 1990, Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass, Br Heart J, 63, 287, 10.1136/hrt.63.5.287 · DOI
  90. Jensen, 2013, Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing, Circulation, 127, 48, 10.1161/CIRCULATIONAHA.111.090514 · DOI
  91. Gray, 2011, Natural history of genotype positive–phenotype negative patients with hypertrophic cardiomyopathy, Int J Cardiol, 152, 258, 10.1016/j.ijcard.2011.07.095 · DOI
  92. Richard, 2012, Advising a cardiac disease gene positive yet phenotype negative or borderline abnormal athlete: is sporting disqualification really necessary?, Br J Sports Med, 46, i59, 10.1136/bjsports-2012-091318 · DOI
  93. Maron, 2015, Circulation, 132, e273
  94. Charron, 2004, Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case, Prenat Diagn, 24, 701, 10.1002/pd.969 · DOI
  95. Kuliev, 2012, PGD for inherited cardiac diseases, Reprod BioMed Online, 24, 443, 10.1016/j.rbmo.2011.12.009 · DOI
  96. Mogensen, 2015, Eur Heart J, 36, 1367, 10.1093/eurheartj/ehv122 · DOI
  97. Meder, 2011, Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies, Circ Cardiovasc Genet, 4, 110, 10.1161/CIRCGENETICS.110.958322 · DOI
  98. Lopes, 2013, Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing, J Med Genet, 50, 228, 10.1136/jmedgenet-2012-101270 · DOI
  99. Oliveira, 2015, A variant detection pipeline for inherited cardiomyopathy–associated genes using next-generation sequencing, J Mol Diagn, 17, 420, 10.1016/j.jmoldx.2015.02.003 · DOI
  100. Bottillo, 2016, Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy, Gene, 577, 227, 10.1016/j.gene.2015.11.048 · DOI
  101. Rehm, 2013, ACMG clinical laboratory standards for next-generation sequencing, Genet Med, 15, 733, 10.1038/gim.2013.92 · DOI
  102. MacArthur, 2014, Guidelines for investigating causality of sequence variants in human disease, Nature, 508, 469, 10.1038/nature13127 · DOI · Paper page
  103. Sherrid, 2016, Drug therapy for hypertrophic cardiomyopathy: physiology and practice, Curr Cardiol Rev, 12, 52, 10.2174/1573403X1201160126125403 · DOI
  104. Hamada, 2014, Advances in medical treatment of hypertrophic cardiomyopathy, J Cardiol, 64, 1, 10.1016/j.jjcc.2014.02.022 · DOI
  105. Olivotto, 2015, INHERIT (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy—a randomised intervention trial with losartan), Glob Cardiol Sci Pract, 7, 1
  106. Marian, 2009, Experimental therapies in hypertrophic cardiomyopathy, J Cardiovasc Transl Res, 2, 483, 10.1007/s12265-009-9132-7 · DOI
  107. Jensen, 2013, Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile, Heart, 99, 1012, 10.1136/heartjnl-2012-303339 · DOI
  108. McLeod, 2007, Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy, Eur Heart J, 28, 2583, 10.1093/eurheartj/ehm117 · DOI
  109. Maron, 2015, The 20 advances that have defined contemporary hypertrophic cardiomyopathy, Trends Cardiovasc Med, 25, 54, 10.1016/j.tcm.2014.09.004 · DOI
  110. Song, 2014, Role of noninvasive imaging modalities to better understand the mechanism of left ventricular outflow tract obstruction and tailored lesion-specific treatment options, Circ J, 78, 1808, 10.1253/circj.CJ-14-0524 · DOI
  111. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  112. Schaff, 2012, Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction, J Thorac Cardiovasc Surg, 143, 303, 10.1016/j.jtcvs.2011.10.059 · DOI
  113. Ferrazzi, 2015, Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy, J Am Coll Cardiol, 66, 1687, 10.1016/j.jacc.2015.07.069 · DOI
  114. Desai, 2013, Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction, Circulation, 128, 209, 10.1161/CIRCULATIONAHA.112.000849 · DOI · Paper page
  115. Sigwart, 1995, Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy, Lancet, 346, 211, 10.1016/S0140-6736(95)91267-3 · DOI
  116. Veselka, 2011, Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years, Can J Cardiol, 27, 763, 10.1016/j.cjca.2011.09.001 · DOI
  117. Jensen, 2011, Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study, Circ Cardiovasc Interv, 4, 256, 10.1161/CIRCINTERVENTIONS.110.959718 · DOI
  118. Sorajja, 2012, Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Circulation, 126, 2374, 10.1161/CIRCULATIONAHA.111.076257 · DOI
  119. Veselka, 2014, Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population, Eur Heart J, 35, 2040, 10.1093/eurheartj/eht495 · DOI
  120. Veselka, 2016, Low procedure-related mortality achieved with alcohol septal ablation in European patients, Int J Cardiol, 209, 194, 10.1016/j.ijcard.2016.02.077 · DOI
  121. Veselka, 2016, Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry, Eur Heart J, 37, 1517, 10.1093/eurheartj/ehv693 · DOI · Paper page
  122. Panaich, 2014, Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from nationwide inpatient sample [1998–2010]), Am J Cardiol, 114, 1390, 10.1016/j.amjcard.2014.07.075 · DOI
  123. Maron, 2015, Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction, J Am Coll Cardiol, 66, 1307, 10.1016/j.jacc.2015.06.1333 · DOI · Paper page
  124. Kim, 2016, Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011, JAMA Cardiol, 1, 324, 10.1001/jamacardio.2016.0252 · DOI
  125. Liebregts, 2015, A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy, JACC Heart Fail, 3, 896, 10.1016/j.jchf.2015.06.011 · DOI
  126. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, New Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  127. Sorajja, 2009, Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study, J Am Coll Cardiol, 54, 234, 10.1016/j.jacc.2009.01.079 · DOI
  128. Fananapazir, 1994, Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy, Circulation, 90, 2731, 10.1161/01.CIR.90.6.2731 · DOI
  129. Maron, 1999, Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover Study (M-PATHY), Circulation, 99, 2927, 10.1161/01.CIR.99.22.2927 · DOI
  130. Nishimura, 1997, Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial, J Am Coll Cardiol, 29, 435, 10.1016/S0735-1097(96)00473-1 · DOI
  131. Kappenberger, 1997, Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study, Eur Heart J, 18, 1249, 10.1093/oxfordjournals.eurheartj.a015435 · DOI
  132. Galve, 2010, Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study, Heart, 96, 352, 10.1136/hrt.2008.158915 · DOI
  133. Vatasescu, 2012, Biventricular/left ventricular pacing in hypertrophic obstructive cardiomyopathy: an overview, Indian Pacing and Electrophysiol J, 12, 114, 10.1016/S0972-6292(16)30503-4 · DOI
  134. Lee, 2014, Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy, Transplant Proc, 46, 1502, 10.1016/j.transproceed.2013.12.052 · DOI
  135. Guttmann, 2014, Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart, 100, 465, 10.1136/heartjnl-2013-304276 · DOI
  136. Wilke, 2016, High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device, J Cardiovasc Electrophysiol, 27, 779, 10.1111/jce.12982 · DOI
  137. Guttmann, 2015, Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk–CVA), Eur J Heart Fail, 17, 837, 10.1002/ejhf.316 · DOI
  138. Haruki, 2016, Stroke and embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation, Stroke, 47, 936, 10.1161/STROKEAHA.115.012130 · DOI
  139. Kumar, 2015, Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy, Card Electrophysiol Clin, 7, 173, 10.1016/j.ccep.2015.03.002 · DOI
  140. Spirito, 1999, Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis, Circulation, 99, 2132, 10.1161/01.CIR.99.16.2132 · DOI
  141. Zemanek, 2008, Infective endocarditis after alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Int Heart J, 49, 371, 10.1536/ihj.49.371 · DOI
  142. Alpert, 2015, Sports and exercise in athletes with hypertrophic cardiomyopathy, Clin Sports Med, 34, 489, 10.1016/j.csm.2015.03.005 · DOI
  143. Tanaka, 2014, Cardiovascular events in pregnancy with hypertrophic cardiomopathy, Circ J, 78, 2501, 10.1253/circj.CJ-14-0541 · DOI
  144. Bharucha, 2015, Sudden death in childhood cardiomyopathy: results from a long-term national population-based study, J Am Coll Cardiol, 65, 2302, 10.1016/j.jacc.2015.03.552 · DOI
  145. Risgaard, 2014, Burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark, Circ Arrhythm Electrophysiol, 7, 205, 10.1161/CIRCEP.113.001421 · DOI
  146. Maron, 2016, Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry, Am J Med, 10.1016/j.amjmed.2016.02.031 · DOI
  147. Elliott, 2006, Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy, Eur Heart J, 27, 1933, 10.1093/eurheartj/ehl041 · DOI
  148. Maron, 2015, Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies, J Am Coll Cardiol, 65, 1915, 10.1016/j.jacc.2015.02.061 · DOI · Paper page
  149. Veselka, 2015, Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy, Can J Cardiol, 31, 1245, 10.1016/j.cjca.2015.02.010 · DOI
  150. Spirito, 2014, Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors, Am J Cardiol, 113, 1550, 10.1016/j.amjcard.2014.01.435 · DOI
  151. Maron, 2016, Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies, Circulation, 133, 62, 10.1161/CIRCULATIONAHA.115.017633 · DOI
  152. Maron, 2013, Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age, Circulation, 127, 585, 10.1161/CIRCULATIONAHA.112.136085 · DOI · Paper page
  153. Jahnlová, 2015, Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy, Int J Cardiol, 186, 3, 10.1016/j.ijcard.2015.03.207 · DOI
  154. O'Mahony, 2012, The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, Heart, 98, 116, 10.1136/hrt.2010.217182 · DOI
  155. Maron, 2015, Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy, Am J Cardiol, 116, 757, 10.1016/j.amjcard.2015.05.047 · DOI
  156. Magnusson, 2015, Hypertrophic cardiomyopathy and implantable defibrillators in Sweden: inappropriate shocks and complications requiring surgery, J Cardiovasc Electrophysiol, 26, 1088, 10.1111/jce.12750 · DOI

Cited by

Sorted by citations

Metadata

Authors
Veselka, J., Anavekar, N. S., & Charron, P.
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-03
Volume
389
Issue
10075
Pages
1253-1267
ISSN
0140-6736
DOI
10.1016/s0140-6736(16)31321-6
Cited by
257
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review